AHRQ's Clancy Discusses Comparative Effectiveness Research/Personalized Medicine Convergence at PMC Conference
November 04, 2009
AHRQ's Clancy Discusses Comparative Effectiveness Research/Personalized Medicine Convergence at PMC Conference
Speaking at a conference hosted by the Personalized Medicine Coalition, Clancy emphasized that AHRQ is in the business of conducting research, not setting healthcare policy. As such, the agency will continue to investigate personalized medicine interventions to inform the work of the CDC and EGAPP.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CDC Group Finds No Evidence to Support Use of LabCorp's ColoSure Test in General Risk Population
March 23, 2011 / Pharmacogenomics Reporter - Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter - New Kennedy/Eshoo Personalized Medicine Bill Tackles Hot Topics in PGx
June 2, 2010 / Pharmacogenomics Reporter - NIH's Genetic Testing Registry to Launch in 2011, But Will Dx Firms, Labs Voluntarily Participate?
March 24, 2010 / Pharmacogenomics Reporter - Q&A: CDC's Khoury Discusses GAPPNet's Strategy to Drive Adoption of Personalized Medicine
July 15, 2009 / Pharmacogenomics Reporter